[1] |
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge[J]. Int J Stroke, 2021,16(2):217-221.
|
[2] |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
|
[3] |
申大魁. 中国地理区域划分的演变研究[J]. 西南农业大学学报(社会科学版), 2012, 10(7):224-226.
|
[4] |
中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 心房颤动基层合理用药指南[J]. 中华全科医师杂志, 2021, 20(2):166-174.
|
[5] |
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial[J]. JAMA, 2005,293(21):2634-2640.
|
[6] |
Hakalahti A, Biancari F, Nielsen JC, et al. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis[J]. Europace, 2015,17(3):370-378.
|
[7] |
Walfridsson H, Walfridsson U, Nielsen JC, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial[J]. Europace, 2015,17(2):215-221.
|
[8] |
Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial[J]. JAMA, 2014,311(7):692-700.
|
[9] |
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure[J]. N Engl J Med, 2018,378(5):417-427.
|
[10] |
Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate[J]. J Am Coll Cardiol, 2004,43(11):2044-2053.
|
[11] |
Willems S, Klemm H, Rostock T, et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison[J]. Eur Heart J, 2006,27(23):2871-2878.
|
[12] |
Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation[J]. J Cardiovasc Electrophysiol, 2012,23(5):447-454.
|
[13] |
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013,369(22):2093-2104.
|
[14] |
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
|
[15] |
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011,365(11):981-992.
|
[16] |
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009,361(12):1139-1151.
|
[17] |
Romero J, Cerrud-Rodriguez RC, Diaz JC, et al. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: a systematic review and meta-analysis[J]. J Cardiovasc Electrophysiol, 2019,30(8):1250-1257.
|
[18] |
Atti V, Turagam MK, Viles-Gonzalez JF, et al. Anticoagulation after catheter ablation of atrial fibrillation: is it time to discontinue in select patient population?[J]. J Atr Fibrillation, 2018,11(4):2092.
|